View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Cel Sci Corp: 1 director

A director at Cel Sci Corp bought 29,197 shares at 6.850USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: July 31, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: July 24, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: July 17, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: July 10, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: July 7, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: July 1, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: June 29, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MarketLine Department
  • MarketLine Department

StemCells, Inc. - Mergers & Acquisitions (M&A), Partnerships & Allianc...

Summary Marketline's StemCells, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by StemCells, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and i...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: February 27, 2020

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Weekly Insider Tables: June 30, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Weekly Insider Tables: June 16, 2018

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

MDP MEREDITH CORP
RUN SUNRUN INC.
RM REGIONAL MANAGEMENT CORP
RDUS RADIUS HEALTH INC.
QTS QTS REALTY TRUST INC. CLASS A
ODP. ODP CORPORATION
MRTX MIRATI THERAPEUTICS INC.
MIC MACQUARIE INFRASTRUCTURE CORPORATION
MELI MERCADOLIBRE INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LXRX LEXICON PHARMACEUTICALS INC.
LMRK LANDMARK INFRASTRUCTURE PARTNERS
A2N6GQ LEGACY RESERVES
LBTYA LIBERTY GLOBAL PLC CLASS A
JCAP JERNIGAN CAPITAL INC.
ITRI ITRON INC.
INT WORLD FUEL SERVICES CORPORATION
INOV INOVALON HOLDINGS INC. CLASS A
IMMU IMMUNOMEDICS INC.
HASI HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
GOGO GOGO INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
GFN GENERAL FINANCE CORP.
GABC GERMAN AMERICAN BANCORP
ERIE ERIE INDEMNITY COMPANY CLASS A
DLTR DOLLAR TREE INC.
DISH DISH NETWORK CORPORATION CLASS A
CPRX CATALYST PHARMACEUTICALS
CLNE CLEAN ENERGY FUELS
CHRISTOPHER & BANKS CORP.
BECN BEACON ROOFING SUPPLY INC.
AXON SIO GENE THERAPIES INC
AVON. AVON PRODUCTS INC.
AMH AMERICAN HOMES 4 RENT CLASS A
ADMA ADMA BIOLOGICS INC
CVM CEL-SCI CORP.
CORE CORE-MARK HOLDING COMPANY INC.
VSI VITAMIN SHOPPE
CET CENTRAL SECURITIES CORP.
CDEV CENTENNIAL RESOURCE DEVELOPMENT INC. CLASS A
GEC GREAT ELM CAPITAL GROUP INC
GWRS GLOBAL WATER RESOURCES
TNXP TONIX PHARMACEUTICALS HOLDING CORP
LCII LCI INDUSTRIES
WOW WIDEOPENWEST INC.
GPMT GRANITE POINT MORTGAGE TRUST INC.
MLNT MELINTA THERAPEUTICS
DOVA DOVA PHARMACEUTICALS INC.
EOLS EVOLUS INC
TACO TACO CABANA INC.
OFG ORIENTAL FINANCIAL GROUP
ORM INC.
HCFT OWENS REALTY MORTGAGE INC
CLBK HUNT COMPANIES FINANCE TRUST
INC.
COLUMBIA FINANCIAL
 PRESS RELEASE

CEL-SCI Announces $1.5 Million NIH SBIR Grant to Support Development o...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases entitled “Preclinical studies of PG70 LEAPS peptide vaccine for rheumatoid arthritis”. The grant in the amount of approximately $1.5 million will provide funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) applicatio...

 PRESS RELEASE

CEL-SCI to Present Today at the 19th Annual Rodman & Renshaw Global In...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), announces Geert Kersten, Chief Executive Officer, will present today at the 19th Annual Rodman & Renshaw Global Investment Conference at 2:10 PM. The presentation will be webcast live. To access the webcast, please visit the Investor Relations Section of CEL-SCI’s website www.cel-sci.com. The webcast replay will remain available for 90 days following the live presentation. About CEL-SCI Corporation CEL-SCI's work is focused on finding the...

 PRESS RELEASE

CEL-SCI to Present at the 19th Annual Rodman & Renshaw Global Investme...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), today announced Geert Kersten, Chief Executive Officer, will be presenting at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City. The presentation will be on September 11, 2017 at 2:10 PM and will be webcast live. To access the webcast, please visit the Investor Relations Section of CEL-SCI’s website w...

 PRESS RELEASE

CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrant...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD and Series EE warrants to December 1, 2017 (close of business). The Series DD and Series EE warrants were issued as part of a financing on December 8, 2016. Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50. All other terms of the warrants have remained the same. ...

 PRESS RELEASE

CEL-SCI Announces $3.5 Million Registered Direct Offering

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American:CVM) today announced it has entered into a definitive agreement with institutional investors for an offering of shares of common stock with gross proceeds of approximately $3.5 million in a registered direct offering. The closing of the offering is expected to take place on or about August 28, 2017, subject to the satisfaction of customary closing conditions. In connection with the offering, CEL-SCI will issue approximately 1,750,000 registered shares of common...

 PRESS RELEASE

U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Canc...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced it has received a letter from the U.S. Food and Drug Administration (FDA) stating that the clinical hold that had been imposed on the Company’s Phase 3 cancer study with Multikine* (Leukocyte Interleukin, Inj.) has been removed and that all clinical trial activities under this Investigational New Drug application (IND) may resume. Multikine is being studied as a potential first-line (before any other cancer treatment is given) immunotherap...

 PRESS RELEASE

CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in De...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) announces that it is extending the expiration date of its Series DD warrants by one month, from August 10, 2017 to September 10, 2017 (close of business). The Series DD warrants were issued as part of a financing on December 8, 2016. Following the Company’s reverse split in June 2017, twenty-five (25) Series DD warrants will be required to purchase one share at an exercise price of $4.50. All other terms of the warrants have remained the same. Abou...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch